Research and experimental development on natural sciences and engineering
ZELLUNA IMMUNOTHERAPY AS
Revenue 2024
NOK 53,000
Operating profit
NOK −109.6m
Equity
NOK 36.0m
Incorporated
2016
Employees
9
Share capital
NOK 2.0m
Key figures · 2024
Current ratio
2.30
Equity ratio
71.5%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -206739.6% | |
| Net margin (%%) | -198418.9% | |
| Return on assets (%%) | -217.3% | |
| Likviditet | ||
| Current ratio | 2.30 | |
| Working capital | 18.7m | |
| Soliditet | ||
| Equity ratio (%%) | 71.5% | |
| Debt-to-equity ratio | 0.40 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.